Histamine Analogue (Vestibular) Pregnancy: There are no adequate data on the use of betahistine in pregnant women; animal studies do not indicate direct or indirect harmful effects on reproductive toxicity, embryonal/foetal development, parturition or postnatal development at clinically relevant exposure. As a precautionary measure it is preferable to avoid use during pregnancy. It is not known whether betahistine is excreted in human milk (it is excreted in rat milk) - the importance of the drug to the mother should be weighed against the benefits of nursing and the potential risks to the child.

Betahistine

Brand names: Serc

Betahistine is an oral histamine analogue used to reduce the frequency and severity of vertigo attacks, and the associated tinnitus and hearing loss, in Ménière's disease.

Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.

Adult dose

Dose: Initial oral treatment 8 to 16 mg three times daily; maintenance doses generally in the range 24 to 48 mg daily

Route: Oral

Frequency: Three times daily initially; the maintenance daily dose should be given in 2 or 3 divided doses throughout the day

Max: Daily dose should not exceed 48 mg

Take preferably with or after meals with a glass of water; taking betahistine with food may help relieve the mild indigestion it can cause. Tablet-strength equivalents given in the SPC: 8 mg tablets 1 to 2 tablets three times a day; 16 mg tablets half to 1 tablet three times a day. For the 24 mg strength the recommended starting dose is 24 mg, and if the maximum daily dose of 48 mg is indicated adults take one 24 mg tablet twice daily (morning and evening). Dosage can be adjusted to suit individual patient needs. Improvement is sometimes observed only after a couple of weeks of treatment, and the best results are sometimes obtained after a few months; there are indications that treatment from the onset of the disease prevents progression and/or loss of hearing in later phases. Renal impairment, hepatic impairment and the elderly: no specific clinical trials available, but post-marketing experience suggests no dose adjustment appears to be necessary. Paediatric population: betahistine tablets are NOT recommended for use in children and adolescents below age 18 due to lack of data on safety and efficacy. Source product: Betahistine 16 mg tablets (UK SPC).

Dose adjustments

Renal

No specific clinical trials available in this patient group, but according to post-marketing experience no dose adjustment appears to be necessary.

Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

Hypersensitivity to betahistine or to any of the excipients
Phaeochromocytoma - as a synthetic analogue of histamine, betahistine may induce release of catecholamines from the tumour resulting in severe hypertension

Side effects

Headache (common)
Nausea and dyspepsia (common)
Mild gastric complaints e.g. vomiting, gastrointestinal pain, dry mouth, diarrhoea, abdominal distension and bloating (frequency not known) - normally managed by taking the dose during meals or lowering the dose
Hypersensitivity reactions, e.g. anaphylaxis (frequency not known)
Cutaneous and subcutaneous hypersensitivity reactions, in particular angioneurotic oedema, urticaria, rash and pruritus (frequency not known); thrombocytopenia (frequency not known)

Interactions

Monoamine oxidase (MAO) inhibitors, including MAO-B selective agents such as selegiline - in vitro data indicate inhibition of betahistine metabolism; caution is recommended with concomitant use
H1 antagonists (antihistamines) - concurrent administration may cause mutual attenuation of the effect of the active agents
No proven cases of hazardous interactions and no in-vivo interaction studies performed; based on in-vitro data no in-vivo inhibition of cytochrome P450 enzymes is expected
Isolated case reports: an interaction with ethanol and with a compound containing pyrimethamine with dapsone, and potentiation of betahistine with salbutamol

Clinical monograph

How it works

It acts as a weak histamine H1-receptor agonist and H3-receptor antagonist; it is thought to improve microcirculation in the inner ear and modulate vestibular activity, although the precise mechanism is not fully established.

Prescribing in practice

Use with caution in asthma and in active or previous peptic ulcer disease, as histaminergic effects may provoke symptoms.
Use caution in phaeochromocytoma; it is generally well tolerated, with mild gastrointestinal upset and headache the commonest effects.
Review the response over time and reconsider the diagnosis or treatment if vertigo is not controlled.

Monitoring

No specific laboratory monitoring is required; assess clinically by the frequency and severity of vertigo, tinnitus and hearing symptoms.

Counselling the patient

Take it with food to reduce stomach upset.
Report worsening wheeze if you have asthma, or indigestion or stomach pain.

Evidence & guidelines

Widely used to reduce the burden of Ménière's-related vertigo; benefit is supported by clinical use and guidance, though trial evidence is mixed.

Reference: British Society of Audiology (BSA) Ménière's Guidelines; NICE Evidence; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Curated clinical cross-links plus same-class fallbacks.

Calculators

Drugs

Betahistine dihydrochloride · Histamine analogue (vestibular)

Pathways